John Miller
Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.
Twitter handle: @jeffmason1
Novartis recruits new compliance head from Siemens after ethics stumbles
ZURICH Novartis has recruited a new chief ethics officer from Siemens after costly bribery scandals and a disputed $1.2 million contract with President Donald Trump's former lawyer that the Swiss drugmaker now calls a mistake.
Upbeat Roche bests rival Novartis as new drugs fuel growth
ZURICH Swiss drugmaker Roche on Thursday outshone crosstown rival Novartis by boosting its 2018 sales outlook, helped by new medicines in a year when many feared patent expirations and cheaper copies would put growth at risk.
Switzerland's UBS boosts profits but trade tensions dim future
ZURICH Switzerland's UBS posted a stronger-than-expected profit in the second quarter of 2018 but the largest money manager for the globe's rich saw a slip in its core business of banking for the wealthy.
Swiss, German drugmakers join U.S. price freeze
ZURICH European drugmakers Roche, Bayer and Merck KGaA became the latest companies to freeze prices in the United States for the rest of 2018 following criticism by President Donald Trump over the cost of medicine.
Roche takes Tecentriq hit on survival data
ZURICH Roche's hopes of clinching more of the lung cancer treatment market with its Tecentriq immunotherapy had a major setback on Thursday, when a trial failed to deliver survival data the Swiss drugmaker needs to challenge rival Merck.
Novartis hints at 2018 outlook hike despite drug price freeze
ZURICH Novartis may ratchet up its 2018 sales outlook, its finance chief said on Wednesday, despite halting planned U.S. drug price hikes amid pressure on the industry from President Donald Trump's administration over the high cost of medicines.
Novartis disputes U.S. senators' report on Cohen contract
ZURICH Novartis on Friday disputed a report from Democratic U.S. senators that concluded the Swiss drugmaker misled the public about its $1.2 million contract with a former attorney for President Donald Trump.
OC Oerlikon pulls IPO for low-profit drives unit
ZURICH Industrial group OC Oerlikon shelved a listing for its drives unit on Monday citing market volatility, adding to signs that the Swiss IPO market, which got off to a strong start this year, is cooling.
Rival Novartis, Gilead CAR-T therapies win European panel recommendation
ZURICH Rival cancer cell therapies from Swiss drugmaker Novartis and U.S.-based Gilead Sciences won a key recommendation from a European Medicines Agency panel, likely clearing their way for approval within months.
Novartis hands investors Alcon spin-off, $5 billion share buyback
ZURICH Novartis plans to spin off its Alcon eye care business to shareholders and buy back up to $5 billion in stock as Chief Executive Vas Narasimhan refocuses the Swiss group on prescription drugs.
Markets
- U.S.
- Europe
- Asia
- Sectors
| DOW | 25,758.69 |
+
89.37 |
+0.35% |
| S&P 500 | 2,857.05 |
+
6.92 |
+0.24% |
| NASDAQ | 7,821.01 |
+
4.68 |
+0.06% |
| TR US Index | 254.76 |
+
0.66 |
+0.26% |
Sector Summary
| Energy |
+0.78%
|
| Basic Materials |
+0.69%
|
| Industrials |
+0.47%
|
| Cyclical Goods & Services |
+0.54%
|
| Non-Cyclical Goods & Services |
+0.17%
|
| Financials |
+0.34%
|
| Healthcare |
+0.36%
|
| Technology |
-0.05%
|
| Telecoms |
+0.06%
|
| Utilities |
-0.22%
|